Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know, right now what I'm hoping for most is another or two complete responses in pancreatic.
This price has NOTHING to do with Marker, it's a virus and oil decline … and what they may mean to future U.S. GDP.
Couldn't help myself - bought more at $2.15.
Question: listen, I've been on this board long enough that you all know me by now and have heard me say that I went way too far in overboard with MRKR stock to the point where it is like 75% of my stock holdings.
I just did my taxes … and I'm thinking about buying more MRKR at these still low prices.
Already put the money in to TD Ameritrade, just ain't bought it yet.
Am I crazy? or what?
Thank You
Yes, I don't know if the new trial will be for pancreatic or something else, that's why I said "no matter what the indication that they will be going after".
I just hope that, no matter what the indication (or disease) they go after, I hope they prepare a customized antigen mix for that indication.
Thank You
Phantom, May I ask you a question? PR said “The financial flexibility provided by this transaction will further support the advancement of our clinical programs including the first Marker-sponsored clinical trial this year investigating our novel MultiTAA cell therapy".
The phrase "first Marker-sponsored clinical trial" leads me to something others (and maybe you) have touched on, and I'd like to ask you about two aspects of it.
#1, Others have suggested that "our" trials are NOT MRKR's trials but are Baylor trials and that may be why we are not properly valued to what we believe we should be.
Is that true? or can you elaborate on it.
#2, and for this I kind of have to stretch to my point. OK, remember for the pancreatic trial MRKR did NOT use a "customized" antigen mix, but rather used the same 5 antigen mix that they were using for AML?
With this "first Marker-sponsored clinical trial", being that this trial will now be MRKR's, no matter what the indication that they will be going after, do you think MRKR will do the smart/right/correct thing and use a "customized" antigen mix?
Thank You
Anybody else please feel free to comment also. Thank You
Sounds like a GREAT - almost one sided deal for MRKR.
"There are no warrants, options, financing swaps, derivatives or other securities associated with this Agreement. Additionally, there are no financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages. Lastly, Marker maintains the right to terminate the Agreement at any time, at its discretion, without any additional cost or penalty."
The cash we need, when we need it, without drastically lowering the share price to entice the investor. Sounds like Aspire Capital really believes in MRKR and just wants the chance to jump even further on to the bandwagon.
Hi Buckboard, I feel your pain. I have to do my taxes soon. I mention that because I also don't recommend stock to people I know. I told 3 friends about MRKR when it was about $8 and they all bought in.
A friend Joe, a friend Tammy, AND my tax accountant Les.
Forty Seven FTSV up 19% on Gilead talks. In sympathy with Forty Seven, Trillium TRIL (same type of company) up 63% today.
As just one of many millions of American stock investors, I'd just like to say: THANKS CHINA
OH Please, I don't want to hold this back down below $2.50 again.
Was hoping we could at least hold the $5 mark.
I am still currently at a profit, but I don't want to sell and miss the really big move up on positive news.
You know, it's funny how the share price affects your thinking.
When we were at $9, I was saying: "NO partnerships with big pharma", the only reason they partner is because they know they will make a ton of "our" money, and I thought we should keep all of "our" money for ourselves within Marker.
Now, after the last year, at $3, I'm like "somebody partner with us on pancreatic cancer". Give us a big name behind us, we'll give them a decent cut of one treatment, and we get an "in" into their worldwide drug distribution network and we keep the rest for "us".
I guess I'm just tired of being down 63% on my largest stock investment.
Just found out where AVXL stock price is going, (hint), it's up.
The stock price is going to the moon.
Well, from below $2.50 to pushing $6 in a very short time ain't a fluke, somebody knows something, and they be buying.
Kind of hoping we see $10+ soon.
Volume of 166,000. Figured there would be much more with the FDA trial hold being lifted.
"So unlike Group 1, this group already has active disease when they get the T-Cells. So a CR is the end point since they have already relapsed."
THANK YOU, now I get it, my brain don't work as good as it used to.
Getting old sucks.
If I remember, we were at about $4 when the FDA put the trial hold on.
OK, hold is off, thought we would bounce up more than almost nothing.
Oh well, back to waiting.
GO PAST $5.
$2 by summer.
Any day now … or … any week now … or … any month now.
DO SOMETHING.
Thanks, I guess if they partner, it would help on two fronts. One is money that is not dilutive and the other would just be the gravitas/influence it would give us … like everybody says: "look, if big bio X believes in MRKR and invests, then there must be something there" and maybe we should jump in too (and the stock price goes up).
I just want to wake up one day and have MRKR pushing $10 again.
Thanks again.
Hi, I don't have an opinion. I just don't know. That's why I asked.
OK, it is GREAT that AVXL has been going up (bout time), but anybody got an opinion as to why? or what the catalyst is?
OK, that helps me understand. Thank You.
BTW: GEEZ, I wish Phantom would say something … his opinion on the hold being lifted? … his opinion on timelines going forward? … his opinion of the possible need for additional capital and when?
Thank You
Thank you for your post and the link. To be honest, I'm a still a bit confused.
In your post it says:
"Trial Design AML: to start early next year. AML= about 26K new cases a year. Trial has 120 patients, 60 adjuvent (T Cells), 60 Std of Care"
I got that part, that is the 120 patients that are referred to in yesterdays PR as "Group 1".
The PR says: "Group 1 will comprise 120 adjuvant (disease-free) patients, with the primary endpoint of relapse-free survival of patients receiving MultiTAA-specific T cell therapy versus a control group."
But then yesterdays PR goes on to say: "Group 2 will comprise 40 active disease patients in a single arm, with primary endpoints of complete remission and duration of complete remission."
I don't get the "Group 2" patients that have the primary endpoints of complete remission.
That's the patients I was referring to. Can you tell me what those 40 people are about?
Thank You.
Howdy, As I stated here before, I'm not a doctor/scientist, but when I read the following:
"Group 2 will comprise 40 active disease patients in a single arm, with primary endpoints of complete remission and duration of complete remission."
I read that to mean, if you Don't get "complete remission", you failed the primary endpoint. There may be something I'm not aware of but I don't see the 30% or 20% you refer to.
I've read trial results of 40/50/60% partial response, or tumors have shrunk by 30/40/50%, or the disease was stabilized and the patient lived on for X amount of months/years … but it seems like None of anything like that would be any good if the end result has to be "complete remission".
If there's something I'm missing here, let me know because the more I learn about this the better off I am. Just because I invest in bio's, don't mean I understand everything that's going on.
GOOD? BAD? Clinical hold lifted and the FDA permitted the Company to initiate its AML trial, beginning with a safety lead-in portion.
On SIX patients, 3 with reagents from old supplier and 3 from new supplier.
Certificate of analysis required by the FDA, by the end of the second quarter of 2020 (JUNE)?
Final technical specifications and comparability data of the new reagents to the FDA during the second half of 2020 (December)?
The safety lead-in will be followed by the 160-patient randomized portion of the study at approximately 20 transplant centers (in 2021)?
First 120 patients, primary endpoint of relapse-free survival.
And 40 patients, primary endpoints of complete remission and duration of complete remission. Primary endpoints of Complete Remission, GEEZ, REALLY? Can you set the bar any higher. Does the FDA want the patients to start peeing liquid gold too.
Seems like a long road timewise, and a very steep upward road at that.
Sure hope we get another or two complete remissions from the patients we are already working with.
ANY OPINIONS: PHANTOM? THELITTLEGUY? XENA? ANYBODY?
Above $5 by next Friday?
Above $1 by next Friday?
I Hope so.
BEAM with nothing but "research" in pipeline goes public with valuation at about 1 Billion.
NO, MRKR's not undervalued at all.
FINALLY above my $3.78 average buy price. First green on this screen in a while.
Held $3. Got $3.50. Got $3.75. GO GO GO, past $4.
40, 40. 41,42,44. Do I hear 50. 50, 50.
I hope it gets up there. I mean seriously, if you cut through all the BS, JUST on potential alone, our price should be much higher if you compare it to many other biotechs that all they have is "potential".
GO PAST 50 cents.
GO PAST $4.
OH, just keep going till it passes $4.